SureTrader SureTrader SureTrader
Home > Boards > US OTC > Medical - Healthcare >

InVivo Therapeutics Holdings Corp (NVIV)

Add NVIV Price Alert      Hide Sticky   Hide Intro
Moderator: TheHound
Search This Board:
Last Post: 1/19/2017 8:12:21 AM - Followers: 196 - Board type: Free - Posts Today: 0

About InVivo Therapeutics 

InVivo Therapeutics Corporation is a Cambridge, MA based medical device company founded to develop and commercialize groundbreaking technologies for the treatment of spinal cord injuries (SCI).Currently, there are no treatment options for SCI patients to successfully restore function following a spinal cord injury. Existing treatments consist of a collection of approaches that only focus on symptoms of SCI, such as decompression and mechanical stabilization of the spinal cord, rather than on the underlying pathology. InVivo intends to develop its novel Neuro-Spinal Scaffold to treat acute SCI and Neuro-Scaffold Plus Stem Cells to treat chronic SCI. - See more at:

In the Spotlight

October 23, 2015 InVivo Therapeutics Reports Significant Improvement of First Patient Implanted with Neuro-Spinal Scaffold™

October 19, 2015   InVivo Therapeutics Announces Expansion of Number of Patients in Pilot Study

October 1, 2015 Early Promise for a New Paralysis Treatment

September 9, 2015 InVivo Therapeutics Announces Mount Sinai Hospital in New York City as New Site for Neuro-Spinal Scaffold™ Clinical Trial

September 8, 2015 InVivo Therapeutics Announces Enrollment of Fifth Patient in Pilot Spinal Cord Injury Study

August 20, 2015 InVivo Therapeutics Announces Enrollment of Fourth Patient in Pilot Spinal Cord Injury Trial

August 13, 2015 InVivo Therapeutics’ CEO and Chairman, Mark Perrin, Interviewed by Maria Bartiromo on FOX Business Network’s “Mornings with Maria”

July 6, 2015 InVivo Therapeutics Reports Significant Improvement of Second and Third Patients Implanted with Neuro-Spinal Scaffold

June 22, 2015 InVivo Therapeutics Receives Notice of Allowance on Patent Covering Broader Compositions for Neuro-Spinal Scaffold and Neuro-Spinal Scaffold Plus Stem Cells

June 5, 2015- InVivo Therapeutics Announces Enrollment of Third Patient in Pilot Spinal Cord Injury Trial

April 16, 2015InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) to Ring The Nasdaq Stock Market Opening Bell

April 8, 2015 - InVivo Therapeutics Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ

March 26, 2015 - InVivo Therapeutics Announces Reopening of Enrollment for Subjects Three through Five for Anticipated Completion of Ongoing Pilot Trial

March 11, 2015 - InVivo Therapeutics Reports 2014 Year End Financial Results and Business Update

February 23, 2015 - InVivo Therapeutics Announces Froedtert & the Medical College of Wisconsin as New Clinical Trial Site for Neuro-Spinal Scaffold

February 9, 2015 - InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer

February 5, 2015 - InVivo Therapeutics Announces CEO Mark Perrin Named Chairman of the Board

February 2, 2015 - Video - Second Implantation of InVivo Therapeutics Neuro-Spinal Scaffold In Charlotte

January 22, 2015 - InVivo Therapeutics Announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial

January 21, 2015 - Zacks Small Cap Research Report- $3.25 Price Target

January 21, 2015 - Jordan's 1st Patient Video

January 21, 2015 - InVivo Therapeutics Reports Three-Month Update of First Acute Spinal Cord Injury Subject Implanted with Neuro-Spinal Scaffold

December 18, 2014 - Microcap - NVIV Research Report **A MUST READ**

December 16, 2014 - InVivo Therapeutics Announces FDA Approval to Expedite Enrollment for Ongoing Pilot Trial

November 11, 2014 - Scottsdale man hopes to walk again after groundbreaking surgery

October 29, 2014 - InVivo Therapeutics Receives FDA Approval to Broaden Inclusion Criteria and Add 14 Additional Sites (20 Total) for Ongoing Pilot Trial

October 15, 2014 - InVivo Therapeutics Announces First Subject Enrolled in Pilot Spinal Cord Injury Trial

April 28, 2014 - InVivo Therapeutics Initiates First Clinical Trial of Neuro-Spinal Scaffold


Ongoing Human Trials:
SEC Filings:
Recent News:
Share Structure:
Investor Presentation:



All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NVIV News: Statement of Changes in Beneficial Ownership (4) 01/20/2017 02:06:29 PM
NVIV News: Statement of Changes in Beneficial Ownership (4) 01/20/2017 02:05:36 PM
NVIV News: Statement of Changes in Beneficial Ownership (4) 01/20/2017 02:05:36 PM
NVIV News: Statement of Changes in Beneficial Ownership (4) 01/20/2017 02:04:33 PM
NVIV News: InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study 01/19/2017 08:00:00 AM
#5292  Sticky Note A Year in Review: 2015 FactMan777 01/03/16 12:24:23 AM
#5688   InVivo Therapeutics Announces New Patient Enrollment into The MDizzle 01/19/17 08:12:21 AM
#5687   InVivo Therapeutics Announces University of New Mexico Hospital MDizzle 01/17/17 08:13:33 AM
#5686   Thanks for sharing MDizzle Perkin78 01/13/17 10:12:12 AM
#5685   JPM Meeting Notes - InVivo Therapeutics (NVIV) MDizzle 01/12/17 03:13:24 PM
#5684 TheHound 01/09/17 07:27:40 PM
#5682   Can someone post the SA article from today? MDizzle 01/09/17 03:26:52 PM
#5681   7. Ownership of Ideas, Copyrights and Patents . twins11 01/09/17 07:48:18 AM
#5680   Exhibit 10.1 InVivo Therapeutics Holdings Corp. One Broadway, 14 th twins11 01/09/17 07:46:06 AM
#5679   CAMBRIDGE, Mass. (June 22, 2015) – InVivo Therapeutics twins11 01/03/17 07:20:43 PM
#5678   InVivo Therapeutics Receives Notice of Allowance on Patent twins11 01/03/17 07:19:02 PM
#5677   InVivo Therapeutics Responds to PixarBio Announcement MDizzle 01/03/17 04:31:34 PM
#5676   All i see is an poor effort by TheHound 01/03/17 01:24:58 PM
#5675   That sure was and "interesting" press release. Tadedge 01/03/17 12:53:09 PM
#5674   Very creative SEC document. Dew thought it was north40000 01/03/17 11:41:21 AM
#5673   I don't see NVIV share holders voting for JB3729 01/03/17 11:40:01 AM
#5672   UNITED STATES JB3729 01/03/17 11:27:45 AM
#5670   Huh? Looks like legit news site: Tadedge 01/03/17 10:40:34 AM
#5669 NANOHUB 01/03/17 10:24:24 AM
#5668   This is the problem with people on social ClimbTheMtns 01/03/17 09:59:58 AM
#5667   Never seen an official PR reading that way, uksausage 01/03/17 09:59:55 AM
#5666   It’s Time to Make US Pharma GREAT Again, JB3729 01/03/17 09:10:14 AM
#5664   Awesome. So is he annoyed yet? DDobserver 12/21/16 02:04:24 PM
#5663   Add. When old CEO gets annoyed it grows. dshade 12/21/16 01:38:11 AM
#5662   The price is in the low 4's what DDobserver 12/14/16 03:51:52 PM
#5658   let's see, back to the low 4's where TheHound 12/08/16 03:51:38 PM
#5657   Lets see. A year behind schedule, little to DDobserver 12/07/16 12:41:44 PM
#5656   gotcha. that makes sense. i think it's been TheHound 11/28/16 08:13:36 PM
#5655   Hound, you just agreed with me last week. BioBull1 11/28/16 07:56:52 PM
#5654   i see no mention of 21 patients in TheHound 11/28/16 03:25:14 PM
#5653   correct. Potentially up to 21 patients per the BioBull1 11/28/16 02:46:25 PM
#5652   9 viable patients in over 2 years? is blackbandit 11/25/16 10:52:17 PM
#5651   That would be incorrect... BioBull1 11/23/16 11:18:13 AM
#5650   9 more patients needed to complete the study. MDizzle 11/22/16 03:40:27 PM
#5649   Agree. In regard to 30 patients, this was what TheHound 11/18/16 11:31:55 AM
#5648   Hound, the clinical trial site has stated June BioBull1 11/18/16 09:16:37 AM
#5647   Anyone know what this device is? uksausage 11/18/16 08:48:33 AM
#5646   u didn't even get the question right. here TheHound 11/18/16 12:19:37 AM
#5645   You asked me what kind of person uses DDobserver 11/17/16 11:08:28 PM
#5644   up-2-date clinical trial info: TheHound 11/17/16 05:17:52 PM
#5643   Have you heard: why the slow down in Devo33 11/17/16 04:35:32 PM
#5642   Who in their right mind looks for intrinsic TheHound 11/17/16 03:40:15 PM
#5641   Perrin has been saying that all year regarding pace. BioBull1 11/17/16 02:40:33 PM
#5639   the SP that was required for NVIV to TheHound 11/17/16 01:23:21 PM
#5638   If I am wrong prove your position show DDobserver 11/17/16 01:18:09 PM
#5637   wrong again. TheHound 11/17/16 12:32:55 PM
#5636   wrong. the minimum bid price requirement stems from TheHound 11/17/16 12:06:40 PM
#5635   "we expect enrollment to increase in the coming Devo33 11/17/16 11:40:55 AM
#5633   InVivo Therapeutics Announces New Patient Enrollment into The MDizzle 11/17/16 08:18:08 AM
#5632   make u smart and disprove ur thoughts? lol. TheHound 11/17/16 12:06:26 AM
#5631   Yes it is up. What happened is market DDobserver 11/16/16 11:12:05 PM